Oppenheimer & Co. Inc. Has $11.55 Million Position in Thermo Fisher Scientific Inc (NYSE:TMO)

Oppenheimer & Co. Inc. reduced its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 17.4% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 75,193 shares of the medical research company’s stock after selling 15,857 shares during the period. Oppenheimer & Co. Inc.’s holdings in Thermo Fisher Scientific were worth $11,549,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Independent Portfolio Consultants Inc. raised its stake in shares of Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock worth $112,000 after buying an additional 2 shares during the last quarter. Sharkey Howes & Javer raised its stake in shares of Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock worth $113,000 after buying an additional 7 shares during the last quarter. Penserra Capital Management LLC raised its stake in shares of Thermo Fisher Scientific by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,150 shares of the medical research company’s stock worth $176,000 after buying an additional 100 shares during the last quarter. South Texas Money Management Ltd. bought a new stake in shares of Thermo Fisher Scientific during the first quarter worth $202,000. Finally, Fairfax Financial Holdings Ltd Can bought a new stake in shares of Thermo Fisher Scientific during the first quarter worth $206,000. Hedge funds and other institutional investors own 87.15% of the company’s stock.

Thermo Fisher Scientific Inc (NYSE TMO) traded down 0.632% during midday trading on Thursday, reaching $172.165. 356,174 shares of the company traded hands. The company has a 50 day moving average price of $176.96 and a 200-day moving average price of $165.20. Thermo Fisher Scientific Inc has a one year low of $139.07 and a one year high of $182.87. The stock has a market capitalization of $67.16 billion, a P/E ratio of 29.994 and a beta of 1.06.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The firm had revenue of $5 billion for the quarter, compared to analyst estimates of $4.92 billion. During the same period in the prior year, the firm earned $2.03 earnings per share. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. Analysts forecast that Thermo Fisher Scientific Inc will post $9.24 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be paid a dividend of $0.15 per share. The ex-dividend date is Thursday, September 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.35%. Thermo Fisher Scientific’s payout ratio is 10.45%.

ILLEGAL ACTIVITY WARNING: “Oppenheimer & Co. Inc. Has $11.55 Million Position in Thermo Fisher Scientific Inc (NYSE:TMO)” was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/2799159/oppenheimer-co-inc-has-11-55-million-position-in-thermo-fisher-scientific-inc-nysetmo.html.

A number of equities research analysts have recently weighed in on TMO shares. Morgan Stanley lifted their target price on shares of Thermo Fisher Scientific from $186.00 to $192.00 and gave the company an “overweight” rating in a research note on Friday, April 28th. Deutsche Bank AG lifted their target price on shares of Thermo Fisher Scientific from $163.00 to $188.00 and gave the company a “buy” rating in a research note on Friday, April 28th. Barclays PLC reaffirmed an “overweight” rating and set a $190.00 target price (up previously from $175.00) on shares of Thermo Fisher Scientific in a research note on Tuesday, May 9th. Leerink Swann set a $187.00 target price on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Thursday, April 27th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $185.00 target price (up previously from $175.00) on shares of Thermo Fisher Scientific in a research note on Saturday, April 29th. One research analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. Thermo Fisher Scientific has a consensus rating of “Buy” and a consensus target price of $188.56.

In related news, CFO Stephen Williamson sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $176.26, for a total transaction of $440,650.00. Following the sale, the chief financial officer now directly owns 37,790 shares in the company, valued at $6,660,865.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the sale, the chief executive officer now owns 269,279 shares in the company, valued at $46,528,718.41. The disclosure for this sale can be found here. Insiders have sold 27,188 shares of company stock worth $4,702,223 over the last 90 days. Insiders own 0.49% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.